ASCO 2023: Discussant: Looking for Prostate Cancer: Will Novel Imaging Light the Way?
Presented by Louise Emmett, MBChB, FRACP
In the Discussant session at the 2023 ASCO annual meeting, Dr. Louise Emmett discussed the current and future states of novel imaging modalities for advanced prostate cancer, highlighting three abstracts from this session.
Read More
ASCO 2022: Molecular-Based Imaging Redefining the Disease Landscape
Presented by Thomas A. Hope, MD
(UroToday.com) At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, a breakout session assessing the best approaches and treatment updates in biochemically recurrent prostate cancer featured a presentation from Dr. Thomas A. Hope discussing the manner in which molecular-based imaging is defining the landscape of prostate cancer.
Read More
AUA 2022: State-of-the-Art Lecture: PSMA Diagnostics and Theranostics
Presented by William J. Aronson, MD
In a podium presentation at the Friday morning plenary of the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. William Aronson presented a State-of-the-Art Lecture on prostate specific membrane antigen (PSMA) Diagnostics and Theranostics.
Read More
APCCC 2022: When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation?
Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Michael Hofman discussing how frequent low-volume disease on conventional imaging becomes high-volume on next-generation imaging. Dr. Hofman started his presentation by noting that there has been an explosion of PSMA PET publications per year from 2001 to 2021:
Read More
APCCC 2022: Advantages of Using Novel Imaging in nmCRPC
Presented by Michael Morris, MD
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of non-metastatic castrate-resistant prostate cancer (nmCRPC), and a presentation by Dr. Michael Morris discussing the advantages of using novel imaging in this disease space.
Read More
APCCC 2022: Impact of Next Generation Imaging: What Is the Optimal (Current) Tracer for PET-Based Imaging for Staging
Presented by Ken Herrmann, MD, MBA
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on high-risk and locally advanced prostate cancer and a presentation by Dr. Ken Herrmann discussing the impact of next generation imaging and the optimal tracer for PET-based imaging for staging.
Read More
APCCC 2022: Are We Ready to Change Management Based on Next-Generation Imaging? YES
Presented by Jason Efstathiou, MD
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on high-risk and locally advanced prostate cancer and a presentation by Dr. Jason Efstathiou arguing for changes in management based on next-generation imaging.
Read More
SUO 2021: Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer: Data Analysis from two Prospective Trials
Presented by Gerald L. Andriole, Jr, MD
The SUO annual meeting included a prostate cancer session and a presentation by Dr. Gerald Andriole discussing the impact of 18F-fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer.
Read More
SIU 2021: Initial Staging with PSMA
Presented by Robert Reiter, MD
The SIU 2021 annual meeting focused on the role of prostate-specific membrane antigen (PSMA) and theranostics in prostate cancer, Dr. Robert Reiter began with a presentation on the role of PSMA-based imaging as a diagnostic tool in the initial staging of patients with prostate cancer.
Read More
ASTRO 2021: Molecular Imaging and Targeted Radionuclide Therapy with PSMA Radiopharmaceuticals
Presented by Ephraim E. Parent, MD
In a special session of the ASTRO and SNMMI held at the 2021 ASTRO Annual Congress, Dr. Parent presented on the role of molecular imaging and targeted radionuclide therapy using PSMA-based radiopharmaceuticals.
Read More
ASTRO 2021: Molecular Imaging with Fluciclovine PET
Presented by Bital Savir-Baruch, MD
In a special session of the American Society for Radiation Oncology (ASTRO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) held at the 2021 ASTRO Annual Congress, Dr. Baruch presented on the role of molecular imaging using Fluciclovine PET imaging. Read More
EAU 2021: Radiotherapy After Radical Prostatectomy in the PSMA-PET Era
Presented by Alberto Bossi, MD
Dr. Alberto Bossi discussed radiotherapy after radical prostatectomy in the PSMA-PET era. Adjuvant radiotherapy is defined as immediate postoperative radiation in the case of extraprostatic extension, positive margins, seminal vesicle infiltration, high Gleason score, or pN+ disease. Salvage radiotherapy is defined as a wait-and-see policy in that radiation is only given in the case of a rising postoperative PSA.
Read More
EAU 2021: Treatment Options for Recurrent mHSPC: The Role of Imaging-Guided Treatments: Surgery
Presented by obias Maurer, MD
The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Meeting included a presentation by Dr. Tobias Maurer discussing the role of imaging-guided surgical treatment for recurrent metastatic hormone sensitive prostate cancer (mHSPC).
Read More
EAU 2021: PSMA In Diagnostics and Treatment
Presented by Karim Fizazi, MD, Ph.D
Dr. Karim Fizazi finished off the thematic session of Treatment Sequencing in Metastatic Prostate Cancer with a presentation on the role of PSMA in diagnostics and treatment of metastatic prostate cancer.
Read More
EAU 2021: TheraP Phase 2 Trial of Lu-PSMA-617 vs Cabazitaxel: Results and Contrasts to the VISION Study
Presented by Michael S. Hofman, MBBS (Hons), FRACP, FAANMS,
The game changing session of the European Association of Urology (EAU)’s 2021 annual meeting included a presentation by Dr. Michael Hofman from the Peter MacCallum Cancer Centre discussing the phase 2 trial of
177Lu-PSMA-617, TheraP, as well as important contrasts/differences between TheraP and VISION.
Read More
EAU 2021: Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
Presented by Johann De Bono, MD, MSc, Ph.D., FRCP, FMedSci
The EAU 2021 Annual Meeting included a presentation by Johann De Bono discussing the VISION trial, a phase 3 study of
177Lu-PSMA-617 in patients with mCRPC. As PSMA is highly expressed in prostate cancer and mCRPC lesions, the combination of PSMA-617 with the beta-emitter lutetium allows for the targeted delivery of ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Read More
ASCO 2021: Applying the Results of the Phase III VISION Trial, Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer to Clinical Practice - Discussion
Presented by Mary-Ellen Taplin, MD
Following Micheal Morris’s presentation of the
results of the phase III VISION trial of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the Plenary Session of the 2021 ASCO, Dr. Mary-Ellen Taplin from the Dana Farber Cancer Institute provided a discussant overview of these data and helped to contextualize how we may apply them to our practices.
Read More
ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
Presented by Micheal Morris, MD
In a plenary presentation at the 2021 ASCO Annual Meeting, Dr. Morris presented the first results of the VISION trial, a phase III study assessing lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Read More
ASCO GU 2021: Lighting the Way: Lutetium in the Treatment Paradigm
Presented by Mike Machaba Sathekge, MD, Ph.D
In a plenary presentation in the Progress and Promise in Treatment Personalization for Advanced Prostate Cancer session at the 2021 American Society of Clinical Oncology Genitourinary (Cancers Symposium (ASCO GU), Dr. Sathekge provided a talk examining the role of Lutetium in prostate cancer.
Read More
SUO 2020: An Update on Imaging of Primary Prostate Cancer
Presented by James Wysock, MD, MSc
At the Society of Urologic Oncology (SUO) Annual Meeting, Dr. James Wysock gave an update on the imaging for primary prostate cancer. Dr. Wysock briefly touched on imaging strategies in both the screening and diagnosis of localized prostate cancer.
Read More
SUO 2020: Impact of PSMA Scans on Clinical Management-Point/Counterpoint
Presented by Matthew R. Cooperberg, MD, MPH and Tanya B. Dorff, MD
To conclude the advances in prostate cancer session Drs. Matthew Cooperberg and Tanya Dorff debated whether prostate-specific membrane antigen (PSMA) imaging should be routinely used in the clinical management of prostate cancer.
Read More
SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging
Presented by Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
At the 2020 virtual Society of Urologic Oncology's (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Read More
EMUC 2020: PSMA PET for Upfront Staging in High-Risk Prostate Cancer
Presented by Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
(UroToday.com) During the Individualized Approach in Advanced Prostate Cancer session at the European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting, Dr. Declan Murphy presents on using prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for upfront staging in high-risk prostate cancer disease. Dr. Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Read More
SIU Virtual Congress 2020: Debate: Imaging in the Definition of Oligometastatic Prostate Cancer - Oligometastatic Disease Should be Defined Based on Novel Imaging Modalities
Presented by Renu Eapen, MD
The Société Internationale d'Urologie (SIU) 2020 Virtual Annual Congress featured a debate discussing imaging definitions for oligometastatic prostate cancer. Dr. Renu Eapen from Australia argued that oligometastatic disease should be defined based on novel imaging modalities.
Read More
SIU Virtual Congress 2020: Debate: Imaging in the Definition of Oligometastatic Prostate Cancer - Oligometastatic Disease Should be Defined Based on Standard Imaging Modalities
Presented by Noel William Clarke, MD
The Société Internationale d'Urologie (SIU) 2020 Virtual Annual Congress featured a debate discussing imaging definitions for oligometastatic prostate cancer. Dr. Noel Clarke from the United Kingdom argued that oligometastatic disease should be defined based on standard imaging modalities.
Read More
EAU 2020: ProPSMA Study: A Prospective Randomised Multi-Centre Study of PSMA-PET/CT Imaging for Staging High Risk Prostate Cancer Prior to Curative-Intent Surgery or Radiotherapy
Presented by Michael S. Hofman, MBBS (Hons), FRACP, FAANMS,
(UroToday.com) As part of the “Game-Changing Session 1” plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting, Dr. Michael Hofman presented results of the proPSMA study which was recently published in the
Lancet.
1 Read More
ASCO 2020: Is PSMA Right on Target?
Presented by Scott T. Tagawa, MD, MS, FACP
There are currently significant imaging deficiencies for men with prostate cancer (Figure 1), with the hope that PSMA imaging-based modalities will address a significant gap in this field. Prostate-specific membrane antigen PSMA is a transmembrane glycoprotein with folate hydrolase activity.
Read More
ASCO 2020: CONDOR, The Impact of PSMA-targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent Prostate Cancer
Presented by Michael J. Morris, MD
Men with biochemically recurrent prostate cancer after definitive local therapy currently have limited imaging modalities in the United States which are sensitive or specific enough to detect tumor recurrence. PSMA PET scans can improve on this detection by detecting cells expressing PSMA protein on their cell surface.
Read More
ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 1: PSMA PET/CT Imaging
Presented by Charles J. Ryan, MD, & Markus Graefen, MD
San Francisco, California (UroToday.com) The first case presented was that of a 54-year-old otherwise healthy man who underwent radical prostatectomy after biopsy-confirmed prostate cancer.
Read More
ASCO GU 2020: PSMA PET Who Should Undergo Advanced Imaging in the Current Era
Presented by Jeremie Calais, MD
San Francisco, California (UroToday.com) Advanced imaging is increasingly being used across all stages of prostate cancer. Dr. Jeremie Calais from UCLA Medical Center discussed
Read More
SUO 2019: Evaluation of Biomarkers 4K Score, SelectMDx and ExoDx™, PSAD, TRUS and MRI for the Detection of High-Grade Prostate Cancer
Presented by Claire M. De La Calle, MD
Washington, DC (UroToday.com) While PSA screening has resulted in decreasing prostate cancer mortality, PSA is also known to be a poorly specific test for the detection of clinically
Read More
SIU 2019: PSMA in Prostate Cancer – Diagnostic to Theranostics
Presented by Renu Eapen, FRACS
Athens, Greece (UroToday.com) Dr. Renu Eapen gave an overview of the role of PET- prostate-specific membrane antigen (PSMA) in prostate cancer and gave a preview of what is to come
Read More
SIU 2019: An Epidemiologist’s View of Prostate Cancer Screening
Presented by Sigrid Carlsson, MD, PhD, MPH
Athens, Greece (UroToday.com) Dr. Carlsson gave an encompassing presentation on prostate cancer screening from the perspective of an epidemiologist.
Read More
ESMO 2019: Invited Discussant (LBA51, LBA52, 848PD, 849PD and 855PD) – Immunotherapy in mCRPC, PSMA Radionuclide Therapy and an Update M0 STAMPEDE Data
Presented by Cora Sternberg, MD
Barcelona, Spain (UroToday.com) Dr. Cora Sternberg summarized the findings from several posters, including three immunotherapy phase 1 or 2 trials, a phase 2 trial of 177Lu-PSMA-617,
Read More
ESMO 2019: Preliminary Results of a Phase I/II Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC
Presented by Scott T. Tagawa, MD, MS
Barcelona, Spain (UroToday.com) PSMA is overexpressed in prostate cancer with limited expression in other organs. Furthermore, prostate cancer is radiosensitive with dose-response (
Read More
EAU 2019: Theranostics: The Future of Functional Imaging
Presented by Stefano Fanti, MD
Barcelona, Spain (UroToday.com) Theranostics is an emerging field of medicine which utilizes targeted cancer therapy based on specific molecular-targeted diagnostic tests. As part of the Imaging in Prostate Cancer plenary session at the 2019 European Association of Urology (EAU) annual meeting in Barcelona, Spain
Read More
EAU 2019: The Imaging Specialist’s Perspective on MRI for Prostate Cancer
Presented by Olivier Rouvière, MD, PhD
Barcelona, Spain (UroToday.com) Dr. Rouviere presented the imaging specialist’s perspective on MRI use in prostate cancer. According to the European Association of Urology (EAU) guidelines prostate multiparametric MRI (mpMRI) was originally recommended after a negative prostate biopsy
Read More
ASCO GU 2019: Results of a 50 Patient Single-Centre Phase II Prospective Trial of Lutetium-177 PSMA-617 Theranostics in mCRPC
Presented by Michael Hofman, FRACP, MBBS
San Francisco, CA (UroToday.com) PSMA is over-expressed in all prostate tissue, including prostatic carcinoma. Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a small radiolabeled molecule which binds to PSMA
Read More
ASCO GU 2019: Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning
Presented by Jeremie Calais, MD, MSc
San Francisco, CA (UroToday.com) Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging
Read More
ESOU 2019: Radiotherapy: High Quality Local Treatment in High Risk Localized Prostate Cancer
Presented by Paul L. Nguyen, MD
Prague, Czech Republic (UroToday.com) Dr. Paul Nguyen took the stance for radiation therapy in this much-anticipated debate regarding appropriate local treatment in men with high risk localized prostate cancer. Dr. Nguyen notes that high-quality radiation therapy for high-risk disease needs long-term ADT and a brachytherapy boost.
Read More